In a double-blind, randomized trial, patients experienced significantly less postoperative pain and recovered approximately two days sooner when they received the new anesthetic, neosaxitoxin. Neosaxitoxin is a site 1 sodium-channel blocker based on molecules derived from aquatic organisms. Unlike other local anesthetics, which usually last for less than eight hours, neosaxitoxin provides local anesthesia for more than 24 hours.
The study was reported in the March-April issue of Regional Anesthesia and Pain Medicine.
Read the BioScholar report on neosaxitoxin.
Read more on anesthesia:
–Abbott Northwestern Hospital Nurse Arrested for Stealing Patient Anesthetic
–Melatonin Can Relieve Surgical Pain in Children Says UC Irvine Anesthesiologist
–Case Study: Artery May Interfere With Cervial Radiofrequency Neurotomy
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.